SK288064B6 - Peptide compounds, pharmaceutical compositions comprising them and their use - Google Patents
Peptide compounds, pharmaceutical compositions comprising them and their use Download PDFInfo
- Publication number
- SK288064B6 SK288064B6 SK75-2003A SK752003A SK288064B6 SK 288064 B6 SK288064 B6 SK 288064B6 SK 752003 A SK752003 A SK 752003A SK 288064 B6 SK288064 B6 SK 288064B6
- Authority
- SK
- Slovakia
- Prior art keywords
- mmol
- solution
- alkyl
- absent
- compound
- Prior art date
Links
- 0 CCCC(C(C(**C(C(*I)=O)*1=CC(C)C=C1)=O)=O)NC(C(CCC1C)*1C([C@@]1NC(OCC(C)*)=*C1(*)*)=*C)=O Chemical compound CCCC(C(C(**C(C(*I)=O)*1=CC(C)C=C1)=O)=O)NC(C(CCC1C)*1C([C@@]1NC(OCC(C)*)=*C1(*)*)=*C)=O 0.000 description 50
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- AHQZRFBZJSCKAV-UHFFFAOYSA-N CC1=CCC=C1 Chemical compound CC1=CCC=C1 AHQZRFBZJSCKAV-UHFFFAOYSA-N 0.000 description 2
- SSDZYLQUYMOSAK-UHFFFAOYSA-N C#CC1CCCCC1 Chemical compound C#CC1CCCCC1 SSDZYLQUYMOSAK-UHFFFAOYSA-N 0.000 description 1
- LBVFELYILXVJOW-HWOCKDDLSA-N CC(C(C1)N([C@@H](C)O)C11CCCC1)O Chemical compound CC(C(C1)N([C@@H](C)O)C11CCCC1)O LBVFELYILXVJOW-HWOCKDDLSA-N 0.000 description 1
- XPHVGKNBNZLSMG-AXAOJVOGSA-N CC(C)(C)[C@@H](C(N(CC1C(C)(C)[C@H]11)C1C(NC(CC1CCC1)C(C(N)=O)=O)=O)=O)NC(NC1(C2)C(C3)CC2CC3C1)=O Chemical compound CC(C)(C)[C@@H](C(N(CC1C(C)(C)[C@H]11)C1C(NC(CC1CCC1)C(C(N)=O)=O)=O)=O)NC(NC1(C2)C(C3)CC2CC3C1)=O XPHVGKNBNZLSMG-AXAOJVOGSA-N 0.000 description 1
- LKENTYLPIUIMFG-UHFFFAOYSA-N CC(C1CCCC1)=O Chemical compound CC(C1CCCC1)=O LKENTYLPIUIMFG-UHFFFAOYSA-N 0.000 description 1
- ONDBKLZMVCQRSS-UHFFFAOYSA-N CC1C2C=COC2BC1 Chemical compound CC1C2C=COC2BC1 ONDBKLZMVCQRSS-UHFFFAOYSA-N 0.000 description 1
- ZKCQLEUZFXIVIE-UHFFFAOYSA-N CCCCC(N(C)C(CC)CC)=O Chemical compound CCCCC(N(C)C(CC)CC)=O ZKCQLEUZFXIVIE-UHFFFAOYSA-N 0.000 description 1
- GSPAVZIEDMALNO-ULUSZKPHSA-N C[C@H](C1NCCCC1)O Chemical compound C[C@H](C1NCCCC1)O GSPAVZIEDMALNO-ULUSZKPHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22010800P | 2000-07-21 | 2000-07-21 | |
PCT/US2001/022678 WO2002008244A2 (en) | 2000-07-21 | 2001-07-19 | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
Publications (2)
Publication Number | Publication Date |
---|---|
SK752003A3 SK752003A3 (en) | 2003-08-05 |
SK288064B6 true SK288064B6 (sk) | 2013-04-03 |
Family
ID=22822095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK75-2003A SK288064B6 (sk) | 2000-07-21 | 2001-07-19 | Peptide compounds, pharmaceutical compositions comprising them and their use |
Country Status (32)
Country | Link |
---|---|
US (4) | US7012066B2 (pt) |
EP (1) | EP1385870B1 (pt) |
JP (3) | JP4298289B2 (pt) |
KR (2) | KR100904788B1 (pt) |
CN (3) | CN1498224A (pt) |
AR (2) | AR033985A1 (pt) |
AT (1) | ATE461207T1 (pt) |
AU (2) | AU7698801A (pt) |
BR (1) | BR0112540A (pt) |
CA (1) | CA2410662C (pt) |
CY (2) | CY1112267T1 (pt) |
CZ (1) | CZ303213B6 (pt) |
DE (2) | DE60141608D1 (pt) |
DK (1) | DK1385870T3 (pt) |
EC (1) | ECSP034438A (pt) |
ES (1) | ES2341534T3 (pt) |
HK (1) | HK1058047A1 (pt) |
HU (1) | HU229997B1 (pt) |
IL (2) | IL153670A0 (pt) |
LU (1) | LU91910I2 (pt) |
MX (1) | MXPA03000627A (pt) |
MY (2) | MY139078A (pt) |
NO (2) | NO332329B1 (pt) |
NZ (1) | NZ523782A (pt) |
PL (1) | PL206255B1 (pt) |
PT (1) | PT1385870E (pt) |
RU (2) | RU2355700C9 (pt) |
SI (1) | SI1385870T1 (pt) |
SK (1) | SK288064B6 (pt) |
TW (1) | TWI324611B (pt) |
WO (1) | WO2002008244A2 (pt) |
ZA (1) | ZA200210312B (pt) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
DK1385870T3 (da) * | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
GB2367816A (en) * | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
IL155842A0 (en) * | 2000-12-12 | 2003-12-23 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
KR100926244B1 (ko) | 2001-07-11 | 2009-11-12 | 버텍스 파마슈티칼스 인코포레이티드 | 브릿지된 바이사이클릭 세린 프로테아제 억제제 |
AU2002348414B2 (en) * | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
ES2332778T3 (es) * | 2002-01-23 | 2010-02-12 | Schering Corporation | Compuestos de prolina como inhibidores de la proteasa serina ns3 para uso en el tratamiento de infeccion por el virus de la hepatitis c. |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
EP2468744A2 (en) * | 2002-04-11 | 2012-06-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
EP2332935A1 (en) | 2003-04-11 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
BRPI0410456B8 (pt) | 2003-05-21 | 2021-05-25 | Boehringer Ingelheim Int | compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação |
AR044694A1 (es) | 2003-06-17 | 2005-09-21 | Schering Corp | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo |
WO2004113272A1 (en) * | 2003-06-17 | 2004-12-29 | Schering Corporation | Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof |
WO2004113295A1 (en) * | 2003-06-17 | 2004-12-29 | Schering Corporation | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
EP2368900A3 (en) * | 2003-07-18 | 2012-07-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2536570A1 (en) | 2003-08-26 | 2005-03-10 | Schering Corporation | Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus |
TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
AU2004274468B2 (en) * | 2003-09-18 | 2009-07-23 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MXPA06003455A (es) * | 2003-09-26 | 2006-05-31 | Schering Corp | Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c. |
AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
AU2004285019B9 (en) | 2003-10-27 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
WO2005051980A1 (en) | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
CN100509784C (zh) * | 2003-12-11 | 2009-07-08 | 先灵公司 | 丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂 |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
DK1713823T3 (da) * | 2004-01-30 | 2010-03-08 | Medivir Ab | HCV NS-3 serinproteaseinhibitorer |
CA2554999A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
EP1719773B1 (en) | 2004-02-24 | 2009-04-15 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
ES2327544T3 (es) | 2004-02-27 | 2009-10-30 | Schering Corporation | Compuestos novedosos como inhibidores de serina proteasa ns3 de virus de hepetitis c. |
CN1946690A (zh) * | 2004-02-27 | 2007-04-11 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物 |
KR20060124725A (ko) | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | C형 간염 바이러스 ns3 프로테아제의 억제제 |
US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
US7173057B2 (en) * | 2004-02-27 | 2007-02-06 | Schering Corporation | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus |
BRPI0508095A (pt) | 2004-02-27 | 2007-07-17 | Schering Corp | compostos como inibidores de ns3 serina protease do vìrus da hepatite c |
EP1737821B1 (en) * | 2004-02-27 | 2009-08-05 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
RS51394B (en) * | 2004-02-27 | 2011-02-28 | Schering Corporation | SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS |
US7381827B2 (en) * | 2004-03-12 | 2008-06-03 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US20050249702A1 (en) * | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
EP1773868B1 (en) * | 2004-05-20 | 2009-07-15 | Schering Corporation | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CA2577812A1 (en) | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
AU2005291918A1 (en) | 2004-10-01 | 2006-04-13 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease inhibition |
BRPI0516737A (pt) * | 2004-10-01 | 2008-04-29 | Scynexis Inc | método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
AU2006252519B2 (en) * | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
WO2006130627A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
AU2006252623A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis C virus |
NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
CN101242816B (zh) * | 2005-06-30 | 2012-10-31 | 维罗贝股份有限公司 | Hcv抑制剂 |
US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
KR101294467B1 (ko) * | 2005-07-25 | 2013-09-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 거대고리형 억제제 |
PL1912997T3 (pl) | 2005-07-29 | 2012-02-29 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
WO2007014924A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
KR20130038947A (ko) | 2005-08-19 | 2013-04-18 | 버텍스 파마슈티칼스 인코포레이티드 | 방법 및 중간체 |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
WO2007041632A2 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
US8329658B2 (en) * | 2005-09-30 | 2012-12-11 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection |
AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
NZ594383A (en) | 2005-11-03 | 2013-05-31 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
EP2392590A3 (en) | 2005-11-11 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
AR056805A1 (es) * | 2005-11-14 | 2007-10-24 | Schering Corp | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados |
CN101384551B (zh) * | 2005-12-22 | 2012-08-29 | 先灵公司 | 制备6,6-二甲基-3-氮杂双环-[3.1.0]-己烷化合物和其对映体盐的方法 |
PL1966130T3 (pl) | 2005-12-23 | 2014-05-30 | Zealand Pharma As | Zmodyfikowane związki mimetyczne lizyny |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2007092645A2 (en) * | 2006-02-09 | 2007-08-16 | Schering Corporation | Novel hcv inhibitor combinations and methods |
JP2009526070A (ja) * | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
MX2008011354A (es) * | 2006-03-03 | 2008-09-15 | Schering Corp | Combinaciones farmaceuticas de inhibidores de proteasa del virus de hepatitis c y del sitio interno de entrada ribosomal del virus de hepatitis c. |
MX2008011429A (es) * | 2006-03-06 | 2008-09-18 | Abbott Lab | Composiciones y metodos de uso de ritonavir para tratar hcv. |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
KR20080104366A (ko) * | 2006-04-11 | 2008-12-02 | 노파르티스 아게 | Hcv 억제제 |
BRPI0710878A2 (pt) * | 2006-04-11 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
JP5592647B2 (ja) * | 2006-04-28 | 2014-09-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 制御された析出による6,6−ジメチル−3−アザ−ビシクロ[3.1.0]ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物 |
CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
US8420122B2 (en) * | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
US8188052B2 (en) | 2006-05-19 | 2012-05-29 | Scynexis, Inc. | Method for the treatment and prevention of ocular disorders |
JP5270538B2 (ja) * | 2006-05-23 | 2013-08-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
RU2419626C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
JP2009539292A (ja) * | 2006-06-02 | 2009-11-12 | ぺリション、クロード、アニー | 活性電子の管理 |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
KR20090042973A (ko) | 2006-08-17 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
CA2659461A1 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
JP2010503671A (ja) * | 2006-09-13 | 2010-02-04 | ノバルティス アクチエンゲゼルシャフト | 大環状hcv阻害剤およびその使用 |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
WO2008070447A2 (en) * | 2006-11-21 | 2008-06-12 | Smithkline Beecham Corporation | Anti-viral compounds |
EP2099778A2 (en) * | 2006-11-21 | 2009-09-16 | Smithkline Beecham Corporation | Amido anti-viral compounds |
CA2673111A1 (en) * | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
WO2008076316A2 (en) * | 2006-12-15 | 2008-06-26 | Schering Corporation | Bisulfite purification of an alpha-keto amide |
ES2439246T3 (es) * | 2006-12-20 | 2014-01-22 | Merck Sharp & Dohme Corp. | Procedimiento de preparación de (1R,2S,5S)-N-[(1S)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2S)-2-[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.0]hexan-2-carboxamida |
EP2468724B1 (en) | 2006-12-21 | 2015-11-18 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
MX2009006880A (es) | 2006-12-22 | 2009-07-03 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
WO2008136815A2 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5, 6-ring annulated indole derivatives and use thereof |
MX2009006878A (es) * | 2006-12-22 | 2009-07-07 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
WO2008086053A1 (en) * | 2007-01-03 | 2008-07-17 | Virobay, Inc. | Hcv inhibitors |
EA016327B1 (ru) * | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
KR20090115970A (ko) * | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
CA2679426A1 (en) * | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
WO2009008913A2 (en) * | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
CA2686138A1 (en) * | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
AP2009005057A0 (en) * | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
WO2009018657A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
MX2010002318A (es) | 2007-08-29 | 2010-03-22 | Schering Corp | Derivados azaindol 2,3-sustituidos para tratar infecciones virales. |
US8614229B2 (en) * | 2007-08-29 | 2013-12-24 | Merck Sharp & Dohme Corp. | Substituted indole derivatives and methods of use thereof |
CN101842353A (zh) * | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2,3-取代的吲哚衍生物 |
JP5443360B2 (ja) | 2007-08-30 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
CA2699280A1 (en) | 2007-09-14 | 2009-03-26 | Schering Corporation | Method of treating hepatitis c patients |
MX2010003916A (es) * | 2007-10-10 | 2010-05-05 | Novartis Ag | Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
WO2009064852A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
EP2222660B1 (en) * | 2007-11-16 | 2014-03-26 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
WO2009073380A1 (en) * | 2007-11-28 | 2009-06-11 | Schering Corporation | Dehydrohalogenation process for the preparation of intermediates useful in providing 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds |
EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
MX2010007022A (es) * | 2007-12-21 | 2010-10-05 | Schering Corp | Proceso para la síntesis de 3-amino-3-ciclobutilmetil-2-hidroxipro pionamida o sus sales. |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
CA2712971A1 (en) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010002428A2 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
CA2727620A1 (en) * | 2008-06-13 | 2009-12-17 | Schering Corporation | Tricyclic indole derivatives and methods of use thereof |
ES2438576T3 (es) | 2008-06-24 | 2014-01-17 | Codexis, Inc. | Procesos biocatalíticos para la preparación de compuestos de prolina bicíclica fusionada considerablemente pura estereoméricamente |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
US8697694B2 (en) | 2008-08-20 | 2014-04-15 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
TW201019939A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
EP2326626B1 (en) | 2008-08-20 | 2013-10-16 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2358736A1 (en) * | 2008-10-15 | 2011-08-24 | Intermune, Inc. | Therapeutic antiviral peptides |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8536114B2 (en) * | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20120244122A1 (en) | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
AR077139A1 (es) | 2009-06-23 | 2011-08-03 | Gilead Sciences Inc | Composiciones farmaceuticas utiles para tratar el vch |
TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
US20110082182A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
BR112012021581A2 (pt) * | 2010-02-25 | 2017-03-21 | Ver Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patiëntenzorg | processo de preparação de alfa-aciloxil beta-formamido amidas |
AU2011224698A1 (en) | 2010-03-09 | 2012-11-01 | Merck Sharp & Dohme Corp. | Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases |
AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US9061041B2 (en) | 2011-04-13 | 2015-06-23 | Merck Sharp & Dohme Corp. | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
ES2572329B1 (es) | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
BR112014005617A2 (pt) | 2011-10-21 | 2017-06-13 | Abbvie Inc | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv |
WO2013072327A1 (en) | 2011-11-14 | 2013-05-23 | Sanofi | Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
WO2013178682A2 (en) * | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Multicomponent process for the preparation of bicyclic compounds |
CN103508918B (zh) * | 2012-06-18 | 2015-09-09 | 上海医药工业研究院 | 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法 |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
WO2014061034A1 (en) * | 2012-10-18 | 2014-04-24 | Msn Laboratories Limited | Process for preparation of boceprevir and intermediates thereof |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014068265A1 (en) | 2012-10-29 | 2014-05-08 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014083575A2 (en) | 2012-11-29 | 2014-06-05 | Mylan Laboratories Ltd | Improved process for the preparation of boceprevir intermediate |
CN103936627B (zh) * | 2013-01-18 | 2016-08-31 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用 |
CN103936818B (zh) * | 2013-01-18 | 2017-09-29 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用 |
CN103936652B (zh) * | 2013-01-18 | 2016-07-06 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用 |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
UY35455A (es) | 2013-03-14 | 2014-09-30 | Onyx Therapeutics Inc | Inhibidores tripeptidicos de la epoxicetona proteasa |
AR095426A1 (es) * | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
CN106458940A (zh) * | 2013-10-24 | 2017-02-22 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制的抑制剂 |
EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
CN106810485A (zh) * | 2015-11-27 | 2017-06-09 | 上海现代制药股份有限公司 | 一种手性联苯吡咯烷酮的制备方法及其中间体 |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | CARBOCYCLIC PROLINAMIDE DERIVATIVES |
KR102595723B1 (ko) * | 2016-06-21 | 2023-10-27 | 오리온 옵탈몰로지 엘엘씨 | 헤테로시클릭 프롤린아미드 유도체 |
EP3472130B1 (en) * | 2016-06-21 | 2022-02-16 | Orion Ophthalmology LLC | Aliphatic prolinamide derivatives |
WO2018073110A1 (en) | 2016-10-20 | 2018-04-26 | Basf Se | Quinoline compounds as fungicides |
EP3571190A1 (en) | 2017-01-23 | 2019-11-27 | Basf Se | Fungicidal pyridine compounds |
BR112019020879A2 (pt) | 2017-04-06 | 2020-04-28 | Basf Se | compostos, composição, uso de um composto de formula i, método para combater fungos fitopatogênicos, semente e intermediários |
DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
EP3927703B1 (en) | 2019-02-19 | 2023-04-05 | Univerza V Ljubljani | Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
JP2024500286A (ja) | 2020-11-23 | 2024-01-09 | エナンタ ファーマシューティカルズ インコーポレイテッド | 新規スピロピロリジン誘導抗ウイルス剤 |
CN117003813B (zh) * | 2021-04-16 | 2024-03-08 | 福建广生中霖生物科技有限公司 | 环修饰的脯氨酸短肽化合物及其应用 |
WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
KR20240035513A (ko) * | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
CN114133350B (zh) * | 2021-12-16 | 2023-05-23 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Paxlovid中间体的制备方法 |
WO2023149981A1 (en) * | 2022-02-07 | 2023-08-10 | Purdue Research Foundation | Compounds for the treatment of sars |
CN114736151B (zh) * | 2022-04-13 | 2023-04-21 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德关键中间体制备方法及化合物的结构式 |
CN115160205B (zh) * | 2022-07-08 | 2024-06-07 | 上海皓鸿生物医药科技有限公司 | 一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177134B (en) * | 1977-07-18 | 1981-07-28 | Richter Gedeon Vegyeszet | Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity |
DE2936099A1 (de) * | 1979-09-06 | 1981-04-02 | Victor Dipl.- Chem. 8000 München Brantl | Pharmakologisch aktive peptide |
JPS5781447A (en) * | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
DE3481913D1 (de) * | 1983-04-27 | 1990-05-17 | Ici America Inc | Prolin-derivate. |
ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
IE62868B1 (en) | 1987-11-18 | 1995-03-08 | Chiron Corp | Hepatitis C virus |
ZA897514B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
EP0381216B1 (en) | 1989-02-01 | 1995-12-27 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
US5359138A (en) | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
US5162500A (en) | 1989-04-15 | 1992-11-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
AU7675491A (en) | 1990-04-04 | 1991-10-30 | Chiron Corporation | Hepatitis c virus protease |
JP2804817B2 (ja) | 1990-04-13 | 1998-09-30 | 財団法人微生物化学研究会 | 3―アミノ―2―オキソ脂肪酸誘導体の製造法 |
JPH04149166A (ja) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | 新規ケト酸アミド誘導体 |
CA2098609A1 (en) | 1990-12-28 | 1992-06-29 | Raymond T. Bartus | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration |
FR2686086A1 (fr) * | 1992-01-15 | 1993-07-16 | Adir | Nouveaux derives de peptides et de pseudopeptides therapeutiquement actifs dans la cascade de coagulation sanguine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO1993015193A1 (en) | 1992-01-31 | 1993-08-05 | Abbott Laboratories | Mammalian expression systems for hcv proteins |
CA2138124A1 (en) | 1992-06-24 | 1994-01-06 | David D. Eveleth, Jr. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
US5514694A (en) | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
US5414018A (en) | 1993-09-24 | 1995-05-09 | G. D. Searle & Co. | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension |
US5843450A (en) | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
US6285380B1 (en) * | 1994-08-02 | 2001-09-04 | New York University | Method and system for scripting interactive animated actors |
US5843752A (en) | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
US5919765A (en) | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5763576A (en) | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
TW442452B (en) | 1996-03-01 | 2001-06-23 | Akzo Nobel Nv | Serine protease inhibitors having an alkynylamino side chain |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
AU4156197A (en) | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
IT1285158B1 (it) | 1996-09-17 | 1998-06-03 | Angeletti P Ist Richerche Bio | Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il |
WO1998013462A1 (en) | 1996-09-24 | 1998-04-02 | The Procter & Gamble Company | Liquid detergents containing proteolytic enzyme, peptide aldehyde and a source of boric acid |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
ATE261988T1 (de) | 1996-12-27 | 2004-04-15 | Boehringer Ingelheim Ca Ltd | Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus |
WO1998037180A2 (en) | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
ATE291032T1 (de) | 1997-08-11 | 2005-04-15 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide |
CA2294562C (en) * | 1997-08-11 | 2005-07-26 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6576613B1 (en) * | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
JP2000256396A (ja) * | 1999-03-03 | 2000-09-19 | Dainippon Pharmaceut Co Ltd | 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤 |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6774212B2 (en) | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
ATE297946T1 (de) | 2000-04-03 | 2005-07-15 | Vertex Pharma | Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease |
DK1385870T3 (da) * | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
-
2001
- 2001-07-19 DK DK01954764.5T patent/DK1385870T3/da active
- 2001-07-19 BR BR0112540-0A patent/BR0112540A/pt not_active IP Right Cessation
- 2001-07-19 CN CNA018131115A patent/CN1498224A/zh active Pending
- 2001-07-19 WO PCT/US2001/022678 patent/WO2002008244A2/en active IP Right Grant
- 2001-07-19 RU RU2003105217/04A patent/RU2355700C9/ru not_active IP Right Cessation
- 2001-07-19 CN CN2011100651916A patent/CN102206247B/zh not_active Expired - Fee Related
- 2001-07-19 AT AT01954764T patent/ATE461207T1/de active
- 2001-07-19 SI SI200130967T patent/SI1385870T1/sl unknown
- 2001-07-19 ES ES01954764T patent/ES2341534T3/es not_active Expired - Lifetime
- 2001-07-19 AU AU7698801A patent/AU7698801A/xx active Pending
- 2001-07-19 AU AU2001276988A patent/AU2001276988B2/en not_active Ceased
- 2001-07-19 MY MYPI20013436A patent/MY139078A/en unknown
- 2001-07-19 EP EP01954764A patent/EP1385870B1/en not_active Expired - Lifetime
- 2001-07-19 US US09/908,955 patent/US7012066B2/en not_active Ceased
- 2001-07-19 SK SK75-2003A patent/SK288064B6/sk not_active IP Right Cessation
- 2001-07-19 HU HU0401730A patent/HU229997B1/hu not_active IP Right Cessation
- 2001-07-19 NZ NZ523782A patent/NZ523782A/en not_active IP Right Cessation
- 2001-07-19 CA CA2410662A patent/CA2410662C/en not_active Expired - Fee Related
- 2001-07-19 MY MYPI20064737A patent/MY143322A/en unknown
- 2001-07-19 KR KR1020037000784A patent/KR100904788B1/ko not_active IP Right Cessation
- 2001-07-19 IL IL15367001A patent/IL153670A0/xx unknown
- 2001-07-19 MX MXPA03000627A patent/MXPA03000627A/es active IP Right Grant
- 2001-07-19 PT PT01954764T patent/PT1385870E/pt unknown
- 2001-07-19 KR KR1020097002011A patent/KR100939155B1/ko not_active IP Right Cessation
- 2001-07-19 CZ CZ20030151A patent/CZ303213B6/cs not_active IP Right Cessation
- 2001-07-19 CN CN2011102287110A patent/CN102372764A/zh active Pending
- 2001-07-19 PL PL366063A patent/PL206255B1/pl unknown
- 2001-07-19 JP JP2002514149A patent/JP4298289B2/ja not_active Expired - Fee Related
- 2001-07-19 DE DE60141608T patent/DE60141608D1/de not_active Expired - Lifetime
- 2001-07-20 TW TW090117804A patent/TWI324611B/zh not_active IP Right Cessation
- 2001-07-20 AR ARP010103450A patent/AR033985A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 ZA ZA200210312A patent/ZA200210312B/en unknown
- 2002-12-25 IL IL153670A patent/IL153670A/en active Protection Beyond IP Right Term
-
2003
- 2003-01-20 NO NO20030272A patent/NO332329B1/no not_active IP Right Cessation
- 2003-01-20 EC EC2003004438A patent/ECSP034438A/es unknown
-
2004
- 2004-02-06 HK HK04100762.2A patent/HK1058047A1/xx not_active IP Right Cessation
-
2005
- 2005-09-30 US US11/241,656 patent/US20060205672A1/en not_active Abandoned
-
2008
- 2008-06-30 RU RU2008126266/04A patent/RU2008126266A/ru not_active Application Discontinuation
- 2008-10-27 JP JP2008275159A patent/JP2009051860A/ja active Pending
- 2008-11-19 AR ARP080105033A patent/AR069373A2/es unknown
-
2010
- 2010-06-16 CY CY20101100554T patent/CY1112267T1/el unknown
- 2010-12-20 US US12/973,020 patent/US20110117057A1/en not_active Abandoned
-
2011
- 2011-04-22 US US13/068,159 patent/USRE43298E1/en active Active
- 2011-12-02 LU LU91910C patent/LU91910I2/fr unknown
- 2011-12-16 CY CY2011020C patent/CY2011020I2/el unknown
-
2012
- 2012-01-13 DE DE201212000004 patent/DE122012000004I1/de active Pending
- 2012-11-05 JP JP2012243691A patent/JP5775505B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-12 NO NO2013003C patent/NO2013003I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK288064B6 (sk) | Peptide compounds, pharmaceutical compositions comprising them and their use | |
JP4563033B2 (ja) | C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド | |
JP4748912B2 (ja) | アルキルおよびアリールアラニンp2部分を含むc型肝炎ウイルスに対する大員環ns3−セリンプロテアーゼ阻害剤 | |
JP4452441B2 (ja) | C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド | |
AU2001276988A1 (en) | Peptides as NS3-serine protease inhibitors of hepatitis C virus | |
US20050249702A1 (en) | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease | |
ES2344890T3 (es) | Nuevos peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
AU2003216064A1 (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change of owner's name |
Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US Effective date: 20121108 |
|
SPCF | Filing of an spc |
Free format text: PRODUCT NAME: BOCEPREVIR; REGISTRATION NO/DATE: EU/1/111/704/001 20110718 Spc suppl protection certif: 2-2013 Filing date: 20130328 |
|
SPCG | Grant of an spc |
Free format text: PRODUCT NAME: BOCEPREVIR; REGISTRATION NO/DATE: EU/1/11/704/001 20110718 Spc suppl protection certif: 134 2-2013 Filing date: 20130328 Extension date: 20260718 |
|
SPCM | Change of validity term of an spc as amended by art. 17 (2) of ec reg. no. 1610/96 and art. 18 of ec reg. no. 469/2009 |
Free format text: FIRST REGISTRATION NO/DATE: EU/1/11/704/001 20110718 Spc suppl protection certif: 134 2-2013 Filing date: 20130328 Extension date: 20260720 |
|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20170719 |